FDA Adds Brain Tumor Warning to Depo-Provera Label After Two-Year Fight Over the Science
In December 2025, the FDA approved new label language warning that Depo-Provera use is linked to meningioma brain tumors, reversing an earlier decision that had rejected Pfizer's own request for the warning in 2024.
Read more →